StevenMarkSorscherMD

Oncology • Winston Salem, NC

Associate Professor, Internal Medicine, Washington University School of Medicine

Join to view full profile

Are you Dr. Sorscher?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 78 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
S Hawthorne Rd
Winston Salem, NC 27157
Phone+1 336-716-2255

Fax+1 314-362-3192

Summary

Dr. Steven Sorscher, MD is an oncologist in Winston Salem, North Carolina. He is currently licensed to practice medicine in North Carolina, South Carolina, and Missouri. He is affiliated with Atrium Wake Forest Baptist and is an Associate Professor at Washington University School of Medicine.

Education & Training

University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
University of MichiganResidency, Internal Medicine, 1985 - 1988
University of Michigan Medical SchoolClass of 1985

Certifications & Licensure

CA State Medical License 1989 - Present
NC State Medical License 2015 - 2025
SC State Medical License 2024 - 2025
MO State Medical License 2005 - 2016
WI State Medical License 1994 - 2009
IA State Medical License 1995 - 2003
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Registry Study of Neoadjuvant Chemoradiation & Transplant for Cholangiocarcinoma Patients Start of enrollment: 2005 Aug 12
Terminated
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells Start of enrollment: 2005 Sep 14
Recruiting
Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer Start of enrollment: 2011 May 10
Active, not recruiting
Phase 1
Registry Study - Whipple at the Splenic Artery Start of enrollment: 2010 Sep 20
Completed
FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma Start of enrollment: 2012 Apr 01
Completed
Phase 1
Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma Start of enrollment: 2009 Dec 16
Completed
Phase 1
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer Start of enrollment: 2012 Dec 11
Completed
Phase 2
Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies Start of enrollment: 2013 May 07
Completed
Phase 1
Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 2
LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer Start of enrollment: 2014 Apr 01
Withdrawn
Phase 2
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells Start of enrollment: 2013 Dec 19
Terminated
Phase 2
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors Start of enrollment: 2013 May 03
Terminated
Phase 1, Phase 2
Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer Start of enrollment: 2013 Nov 08
Completed
Phase 2
Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer Start of enrollment: 2014 Aug 01
Withdrawn
Phase 2
Gene Expression and FDG PET/MRI in Evaluating Treatment Response in Patients With Locally Advanced Rectal Cancer Undergoing Chemotherapy and Radiation Therapy Before Surgery Start of enrollment: 2014 Jun 01
Terminated
Phase 1
Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity Start of enrollment: 2014 Jul 07
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

6 citations
EGFR mutations and sensitivity to gefitinib.
Steven M Sorscher
The New England Journal of Medicine. 2004-09-16
73 citations
A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma
Andrea Wang-Gillam, Stacey Plambeck-Suess, Peter S. Goedegebuure, Peter O. Simon, Jonathan B. Mitchem
Investigational New Drugs. 2013-06-01
93 citations
FDA-approved drugs.
Steven Sorscher
Journal of the National Comprehensive Cancer Network. 2010-12-01

Press Mentions

Renato Martins, MD, MPH on Germline Testing in Lung CancerNovember 25th, 2022
Pathogenic Germline Variants ID’d in Patients with Lung CancerAugust 22nd, 2022
Why Was Downstate Dixon Embezzler Released from Prison Eight Years Early?August 8th, 2021
Join now to see all